JPRN-UMIN000001653已完成4 期
A non-blind, randomized, parallel group comparative trial to study the efficacy and safety of Mao-to in the treatment of influenza. - Exploratory evaluation of the efficacy and safety of Mao-to in the treatment of influenza.
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Administration of Kampo medicine or any respiratory medication within 3 days prior to registration. 2) Administration of influenza vaccination within 2 weeks prior to registration. 3) Serious disease complication including, but not limited to: liver, kidney, heart, lung, circulatory, or metabolic disorder. 4) Suspicion of supervening bacterial infection of the respiratory tract. 5) History of drug allergies. 6) Females who are pregnant, lactating or planning pregnancy. 7) Administration of another investigational drug within 4 weeks prior to registration or during the study period, or planned participation in another study. 8) Contraindications to acetaminophen (peptic ulcer, aspirin-induced asthma, acetaminophen hypersensitivity). 9) Subjects who are unfit for the study as judged by the research director, research staff, or others (referred to as "research director and team")
研究者
相似试验
尚未招募
3 期
A clinical trial of herbal products in the management of knee osteoarthritisCTRI/2023/07/054799Phytoveda Pvt. Ltd.
尚未招募
Unknown
Clinical study of nutritional formulations in the management of knee osteoarthritis.CTRI/2024/07/070163ife Synergy
已完成
不适用
Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean feverfamilial Mediterranean feverJPRN-UMIN000028010Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences23
招募中
1 期
A randomised, double blind, parallel group, comparative Phase I study to evaluate the safety and pharmacokinetics of a single intravenous dose of GB221 compared to Herceptin Registered Trademark (trastuzumab) in healthy volunteers.ACTRN12611001171909Genor Biopharma32
进行中（未招募）
1 期
A double-blind, randomized, parallel group comparison of Nizoral® cream (F012), ketoconazole 2% cream (F126) and placebo (F000) in the treatment of interdigital Tinea Pedis. - Ketoconazole cream formulations in Tinea pedisFor the treatment of tinea pedisEUCTR2006-006513-33-GBJanssen Pharmaceutica NV